StockNews.AI
TVTX
StockNews.AI
112 days

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

1. TVTX's FILSPARI receives standard marketing authorization in Europe. 2. This approval expands its availability for IgA nephropathy treatment.

2m saved
Insight
Article

FAQ

Why Very Bullish?

Standard marketing authorization typically leads to increased sales and market acceptance. Historical cases show positive price movements following similar approvals.

How important is it?

The transition from CMA to MA significantly enhances market presence and revenue potential. This is often viewed favorably by investors and analysts.

Why Long Term?

The approval allows TVTX to capture market share and revenue over the long term. Similar approvals have had sustained positive impacts on company valuations.

Related Companies

CSLNVSBMY
SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard MA is granted for all member states of the Euro.

Related News